Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine

ABSTRACT This study investigated the immunomodulatory influence of IL10 producing B regulatory cells, Bregs (CD19+CD24hiCD38hi) to standard Twinrix® vaccination. We also investigated HBsAg specific T-cell mediated IFN-γ responses to Twinrix® which in theory could provide effective immunity despite low anti-HBs titer. A total of 309 hepatitis B negative health care students and workers completed a standard Twinrix® vaccination schedule (0, 1 and 6 months). Depending on the vaccination response the participants were divided in to non-, low- and high responders according to anti-HBs titer (<10, <100 and >1000 mIU/mL respectively) two months after completed vaccination schedule. Blood samples from baseline and after vaccination from all non- and low-responders (23 participants) and the same number of high-responders were used for flow cytometric analyses of IL10 producing Bregs and T-cell mediated IFN-γ responses. A decrease in levels of IL10 producing Bregs was observed after vaccination in high responders compared to non- and low-responders. Compiling non-and low-responders against high-responders showed a lower T-cell mediated IFN-γ response at baseline in non-and low-responders when stimulated with Engerix® vaccine. In contrary no positive correlation between IL10 producing Bregs or IFN-γ positive T-cells and anti-HBs titer was observed. Hence this study cannot prove that levels of IL10 producing Bregs or IFN-γ positive T cell affect HBV vaccine response.

[1]  K. Stiasny,et al.  Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10 , 2013, The Journal of Immunology.

[2]  G. Grosso,et al.  Long-Term Persistence of Seroprotection by Hepatitis B Vaccination in Healthcare Workers of Southern Italy , 2012, Hepatitis monthly.

[3]  B. McMahon,et al.  Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program , 2011, Hepatology.

[4]  F. Meurice,et al.  Five-year post vaccination efficacy of hepatitis B vaccine in rural Nigeria , 2011, Human vaccines.

[5]  P. van Damme,et al.  Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. , 2011, Journal of travel medicine.

[6]  A. Frydén,et al.  Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. , 2008, The Journal of infectious diseases.

[7]  E. Shankar,et al.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. , 2008, World journal of gastroenterology.

[8]  F. P. De la Hoz,et al.  Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  P. van Damme,et al.  Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. , 2006, Vaccine.

[10]  W. Jilg,et al.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. , 2006, Vaccine.

[11]  C. Freitag,et al.  A functional polymorphism in the IL‐10 promoter influences the response after vaccination with HBsAg and hepatitis A , 2005, Hepatology.

[12]  M. Béné,et al.  Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. , 2004, Vaccine.

[13]  K. Reisinger,et al.  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. , 2001, Vaccine.

[14]  M. Kundi,et al.  Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. , 2001, Vaccine.

[15]  H. Whittle,et al.  What level of hepatitis B antibody is protective? , 1999, The Journal of infectious diseases.

[16]  K. Meyer zum Büschenfelde,et al.  Kinetics of hepatitis B surface antigen–specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma , 1999, Hepatology.

[17]  P. van Damme,et al.  The first combined vaccine against hepatitis A and B: an overview. , 1999, Vaccine.

[18]  C. Morimoto,et al.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans , 1991, The Journal of experimental medicine.